Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Sponsor: Nantes University Hospital
Summary
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
2100
Start Date
2021-04-01
Completion Date
2024-05-01
Last Updated
2024-05-07
Healthy Volunteers
No
Interventions
Estimated anticoagulant level (conversion factor x anti-Xa activity)
Estimated anticoagulant level (conversion factor x anti-Xa activity)
Locations (1)
Nantes University Hospital
Nantes, Loire-Atlantique, France